UNSPSC 51381904: Oxolamine

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H19N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 90BEA145GY, chemically known as 1,2,4-oxadiazole, 5-(2-(diethylamino)ethyl)-3-phenyl- but generally known as oxolamine, which bears US NIH Compound Identifier 13738. European Medicines Agency schedules Oxolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09547MIG. The term OXOLAMINE is an International Non-Proprietary Name.

UNSPSC 51381904 Oxolamine is a Commodity code that captures state and local procurement of pharmaceutical products and related health-related substances, though recent activity shows the code applied primarily to naloxone procurement and broader generic pharmaceutical supply agreements rather than oxolamine specifically. State and local buyers under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida has solicited naloxone and drug deactivation systems through competitive bidding to support community health initiatives with quarterly deliveries, while Texas HHS has issued exploratory requests for information on direct-to-manufacturer prescription programs and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration has pursued generic pharmaceuticals and OTC products through a multi-award RFP reaching participating state and local facilities across multiple states including Oregon.

Recent activity concentrates in the South and Midwest, with Florida and Texas generating state-level or county-level demand and Minnesota anchoring a regional cooperative vehicle serving a multi-state membership. Seminole County's IFB60459723LAS, posted June 30, 2026 with a response deadline of July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract carries a two-year initial term with a one-year renewal option and requires drug-free workplace and E-Verify compliance with potential FEMA funding. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription capabilities for future program design. MMCAP's S1070000015802 RFP, due March 26, 2026, establishes multiple contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness; participating vendors must comply with cGMP and Drug Supply Chain Security Act requirements and maintain commercial general liability insurance of $5,000,000 per occurrence.